Estradiol Patch — Systemic Estrogen Support Through Transdermal Delivery

Route: Transdermal patch — continuous systemic delivery.

• Apply to clean, dry, intact, non-irritated skin on the lower abdomen, upper buttock, or outer upper arm (avoid breasts and waistline).
• Rotate application sites; do not reapply to same site within 7 days.
• Press firmly with the palm for at least 30 seconds, ensuring full edge adhesion.
• Change frequency (once-weekly or twice-weekly) is prescribed and must be followed to maintain consistent estradiol levels.
• Old patch should be folded adhesive-to-adhesive and discarded safely, away from children and pets.
• Do not cut patches to modify dose unless specifically instructed by the prescriber.

Final dosing — expressed as daily release rate (mcg/day) and change frequency — is determined by the prescriber based on indication, symptom severity, laboratory values, and individual patient factors. General pharmacological reference points include:

• Standard commercial transdermal estradiol delivers 0.025–0.1 mg/day, with twice-weekly or once-weekly application schedules.
• Lower delivery rates (0.025–0.0375 mg/day) are often used for bone protection or in older patients; higher rates (0.05–0.1 mg/day) for symptomatic vasomotor or genitourinary control.
• Patients with intact uteri require concomitant progestogen — prescriber determines the appropriate progestogen regimen.
• All dosing and application schedule decisions are at the prescriber's discretion.

• Estradiol (17β-estradiol): Binds with high affinity to nuclear estrogen receptors ERα and ERβ, triggering receptor dimerization, translocation to the nucleus, binding to estrogen response elements (EREs), and transcriptional regulation of target genes governing bone remodeling (osteoclast suppression), vasomotor stability (hypothalamic thermoregulation), genitourinary epithelial maintenance, and cardiovascular lipid profiles. Non-genomic signaling through membrane-bound GPER occurs rapidly and contributes to vasodilatory and neuroprotective effects. Transdermal delivery avoids first-pass hepatic metabolism, providing more stable serum concentrations and smaller effects on coagulation proteins and triglycerides compared to oral estradiol.

Clinical Context: Transdermal estradiol is used for systemic hormone replacement in peri- and postmenopausal women experiencing vasomotor symptoms (hot flashes, night sweats), genitourinary syndrome of menopause (GSM), and for prevention of osteoporosis. Transdermal estradiol is preferred by many clinicians over oral estradiol due to lower thromboembolic risk (avoidance of first-pass hepatic effect on clotting factors) and more stable serum levels.

Monitoring Considerations:

• Serum estradiol levels may be checked at follow-up to confirm therapeutic range.
• Endometrial monitoring in non-hysterectomized patients receiving concomitant progestogen.
• Annual or biennial mammography per breast cancer screening guidelines.
• Blood pressure, lipid panel, and clinical symptom reassessment at least annually.
• Reassess ongoing need at least annually; use lowest effective dose for shortest duration consistent with treatment goals.

Contraindications:

• Known, suspected, or history of estrogen-dependent malignancies (breast, endometrial cancer).
• Undiagnosed abnormal genital bleeding.
• Active or history of deep vein thrombosis, pulmonary embolism, or arterial thromboembolic disease (stroke, MI).
• Active liver disease or hepatic impairment.
• Thrombophilic disorders (protein C, protein S, antithrombin deficiency).
• Pregnancy.
• Known hypersensitivity to estradiol or patch components.

Warnings & Precautions:

• Endometrial cancer: Unopposed estrogen in non-hysterectomized women requires concurrent progestogen.
• Breast cancer: Risk increases with prolonged combined estrogen-progestogen use; reassess annually.
• Cardiovascular: Risk of stroke and VTE; risk may be lower with transdermal versus oral route.
• Patch site reactions: Pruritus, erythema, and contact dermatitis at application site.
• Application site rotation: Required to minimize skin irritation and ensure consistent absorption.

Drug Interactions:

• CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort): reduce estradiol levels.
• CYP3A4 inhibitors (ketoconazole, erythromycin): increase estradiol exposure.
• Thyroid hormone: estrogen may increase TBG — monitor thyroid function in hypothyroid patients on levothyroxine.

Common Side Effects: Application site reactions (pruritus, redness, contact dermatitis), breast tenderness, headache, nausea, bloating, irregular spotting or bleeding (without progestogen), and mood changes.

Store patches in original sealed pouches at or below 30°C (86°F); do not freeze. Keep away from heat and direct sunlight. Do not refrigerate unless directed by the compounding pharmacist. Store out of reach of children. Each pouch is single-use — apply immediately after opening. Observe the beyond-use date assigned by Genesis Compounding; do not use after this date.

Why is a transdermal patch preferred over oral estradiol?

Transdermal delivery bypasses first-pass hepatic metabolism, resulting in more stable serum estradiol concentrations and a lower impact on clotting factors and triglycerides. Many clinical guidelines suggest transdermal estradiol carries a lower thromboembolic risk than oral formulations, though prescribers should individualize based on patient history.

Do I need a progestogen with this patch?

If you have an intact uterus, yes — concurrent progestogen is required to prevent estrogen-induced endometrial hyperplasia and cancer. Prescribers determine the appropriate progestogen type, dose, and schedule. Hysterectomized patients may use estrogen alone.

What if the patch falls off early?

Apply a new patch to a clean, dry alternate site and continue your scheduled change day. If frequent detachment occurs, ensure skin is oil-free before application. Contact Genesis Compounding for guidance on adhesion optimization.

Is this product FDA-approved?

This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding and is not FDA-approved as a finished compounded drug product. FDA-approved commercial estradiol patches are available and should be considered when a commercially available product meets clinical needs.

How do I dispose of used patches?

Fold the used patch with the adhesive sides together and dispose of it in a secure household waste container away from children and pets. Do not flush patches down the toilet. Residual estradiol in used patches can be harmful to children and animals.